PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

The goal of this Phase II clinical trial (The PHOENIX Study) is to evaluate if the combination of QL1706 (Iparomlimab and Tuvonralimab), bevacizumab, and chemotherapy can treat patients with TKI-refractory, driver-gene positive (e.g., EGFR, ALK, ROS1, RET, KRAS, BRAF, HER2), non-squamous non-small cell lung cancer (NSCLC) who have high PD-L1 expression (TPS ≥50%). The main question\[s\] it aims to answer \[is/are\]: Does the quadruple combination therapy improve the Objective Response Rate (ORR) compared to historical chemotherapy data? What are the secondary efficacy outcomes, including Pro

Trial Details

NCT ID
NCT07416058
Phase
PHASE2
Sponsor
Guangdong Association of Clinical Trials
Status
RECRUITING
Cancer Type
Squamous Cell Lung Cancer
Interventions
  • QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Locations (sample)
  • Guangzhou, Guangdong,China, China|23.11667,113.25
  • Guangzhou, Guangdong,China, China|23.11667,113.25

Key Eligibility Criteria

  • The study will enroll adult patients (aged 18-75 years) with histologically confirmed locally advanced or metastatic NSCLC (AJCC 9th Edition, Stage…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Lung Cancer Trials on Trialify →